Long Awaited-for Vaccine
Scientists from the Yaroslavl Pharmaceutical Cluster have developed a nanovaccine for herpes infections currently extremely wide-spread. There is no doubt that the vaccine will be popular both in Russian and abroad. Treatment options are quite scarce. The vaccine has no equivalents either in Russia or abroad.
Pilot batches of the vaccine were manufactured in Yaroslavl, and now production is established in Pereslavl Zalessky.
The key benefit of nanovaccine over other herpes drugs implies its unique technology of production based on Vero B cells (African green monkey renal cells) sensitive to all viral effects.
“This drug has been developed by our scientists, says Ellada Mordvintseva, General Manager of Vitafarma. – No country in the world has managed to develop anything of the same order. We receive letters from Germany, America, recently I’ve received a letter from Greece. Herpes is a global problem”.